Treatment related changes in antifibrinolytic activity in patients with polycythemia vera

Hematology

Volumn 15, Issue 6, 2010, Pages 391-396

  Sonmez, Mehmet ^a   Saglam, Fatma ^a   Karahan, S Caner ^a   Erkut, Nergiz ^a   Mentese, Ahmet ^a   Sonmez, Bircan ^a   Ucar, Fahri ^a   Topbas, Murat ^a   Ovali, Ercument ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

5 hydroxyurea; antifibrinolytic activity; phlebotomy; Polycythemia vera

Indexed keywords

5 HYDROXYUREA; ALPHA 2 ANTIPLASMIN; ANTIFIBRINOLYTIC AGENT; HEMOGLOBIN; HYDROXYUREA; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOSIS;

ADULT; AGED; ALPHA-2-ANTIPLASMIN; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; PHLEBOTOMY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYTHEMIA VERA; THROMBOMODULIN; THROMBOSIS;

EID: 78649383771     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12719010991740     Document Type: Article

References (33)

1. Cao M, Olsen RJ, Zu Y. Polycythemia vera: new clinicopathologic perspectives. Arch Pathol Lab Med 2006; 130: 1126-1132.
2. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190-2198.
3. Cervantes F, Arellano-Rodrigo E, Alvarez-Larrán A. Blood cell activation in myeloproliferative neoplasms. Haematologica 2009; 94: 1484-1488.
4. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006; 19: 617-633.
5. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myelopro-liferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22: 2020-2028.
6. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008; 22: 1494-1502.
7. Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 2008; 93: 331-335.
8. Caramazza D, Caracciolo C, Barone R et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol 2009; 88: 967-971.
9. Elliott MA, Tefferi A. Thrombosis and haemorrhage in poly-cythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290.
10. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52: 14-20.
11. Rość D, Kremplewska-Nalezyta E, Gadomska G, Drewniak W, Koczubik W. Plasminogenesis in blood of patients with chronic myeloproliferative syndromes. Pol Arch Med Wewn 2006; 115: 23-28. (Pubitemid 44047460)
12. Evangelista V, Piccardoni P, White JG, de Gaetano G, Cerletti C. Cathepsin G-dependent platelet stimulation by activated poly-morphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin-mediated cell-cell adhesion. Blood 1993; 81: 2947-2957.
13. Falanga A, Marchetti M, Evangelista V et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506-2514.
14. Falanga A, Marchetti M, Evangelista V et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-4266.
15. Musolino C, Alonci A, Bellomo G et al. Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology 2000; 4: 397-402.
16. Maeda NY, Lopes AA, da-Rocha TR, Chamone DA. Plasma anticoagulant system in patients with pulmonary hypertension. Braz J Med Biol Res 1990; 23: 251-254.
17. Wieczorek I, MacGregor IR, Prescott RJ, Ludlam CA. The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera. Blood Coagul Fibrinolysis 1992; 3: 823-826.
18. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastruc-tural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299.
19. Higazi AA, Mazar A, Wang J et al. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 1996; 87: 3545-3549. (Pubitemid 26129580)
20. Senno SL, Pechet L. Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature. J Thromb Thrombolysis 1999; 8: 105-112.
21. Cancelas JA, Garćia-Avello A, García-Frade LJ. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 1994; 75: 513-520.
22. Kaftan O, Balcik OS, Cipil H et al. Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis. Clin Appl Thromb Hemost 2005; 11: 449-454.
23. Fields W, Freeman NJ. The hypercoagulability of polycythemia vera. Hosp Pract 1993; 28: 65-68, 72-73.
24. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 1986; 23: 167-171.
25. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005; 42: 239-247. (Pubitemid 41400665)
26. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-4290.
27. Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23: 455-461.
28. McMullin MF, Bareford D, Campbell P et al. Guidelines for the diagnosis, investigation and management of polycythaemia/ery-throcytosis. Br J Haematol 2005; 130: 174-195.
29. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19: 1-10.
30. Pardanani AD, Levine RL, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
31. Maugeri N, Giordano G, Petrilli MP et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4: 2593-2598.
32. Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008; 93: 1723-1727.
33. Spanoudakis E, Bazdiara I, Kotsianidis I et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and poly-cythemia vera (PV) patients. Ann Hematol 2009; 88: 629-632.